Nakai H - Search Results

1

Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer.

Nakai H, Watanabe Y, Ueda H, Hoshiai H. Nakai H, et al. Cancer Lett. 2007 Jun 18;251(1):164-7. doi: 10.1016/j.canlet.2006.11.017. Epub 2007 Jan 9. Cancer Lett. 2007. PMID: 17215078

2

Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget's disease.

Watanabe Y, Hoshiai H, Ueda H, Nakai H, Obata K, Noda K. Watanabe Y, et al. Among authors: nakai h. Int J Gynecol Cancer. 2002 May-Jun;12(3):304-7. doi: 10.1046/j.1525-1438.2002.01126.x. Int J Gynecol Cancer. 2002. PMID: 12060453

3

Cytopathologic and clinicopathologic features of ovarian hepatoid carcinoma. A case report.

Watanabe Y, Umemoto M, Ueda H, Nakai H, Hoshiai H, Noda K. Watanabe Y, et al. Among authors: nakai h. Acta Cytol. 2003 Jan-Feb;47(1):78-82. doi: 10.1159/000326479. Acta Cytol. 2003. PMID: 12585035

4

Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.

Watanabe Y, Nakai H, Ueda H, Nozaki K, Hoshiai H, Noda K. Watanabe Y, et al. Among authors: nakai h. Cancer Lett. 2003 Oct 28;200(2):173-6. doi: 10.1016/s0304-3835(03)00413-0. Cancer Lett. 2003. PMID: 14568172

5

Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.

Watanabe Y, Nakai H, Ueda H, Hoshiai H. Watanabe Y, et al. Among authors: nakai h. Gynecol Oncol. 2005 Feb;96(2):323-9. doi: 10.1016/j.ygyno.2004.09.029. Gynecol Oncol. 2005. PMID: 15661216 Clinical Trial.

6

The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide.

Watanabe Y, Nakai H, Hoshiai H. Watanabe Y, et al. Among authors: nakai h. Curr Med Res Opin. 2005 Mar;21(3):363-8. doi: 10.1185/030079905X36404. Curr Med Res Opin. 2005. PMID: 15811204

7

Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.

Watanabe Y, Nakai H, Ueda H, Nozaki K, Hoshiai H. Watanabe Y, et al. Among authors: nakai h. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):224-7. doi: 10.1111/j.1525-1438.2005.15207.x. Int J Gynecol Cancer. 2005. PMID: 15823103 Free article.

8

Microsatellite status and immunohistochemical features of ovarian clear-cell carcinoma.

Ueda H, Watanabe Y, Nakai H, Hemmi H, Koi M, Hoshiai H. Ueda H, et al. Among authors: nakai h. Anticancer Res. 2005 Jul-Aug;25(4):2785-8. Anticancer Res. 2005. PMID: 16080527 Free article.

9

Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix.

Watanabe Y, Nakai H, Shimaoka M, Tobiume T, Tsuji I, Hoshiai H. Watanabe Y, et al. Among authors: nakai h. Int J Clin Oncol. 2006 Aug;11(4):309-13. doi: 10.1007/s10147-006-0567-4. Int J Clin Oncol. 2006. PMID: 16937305 Clinical Trial.

10

Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer.

Hata K, Dhar DK, Watanabe Y, Nakai H, Hoshiai H. Hata K, et al. Among authors: nakai h. Eur J Cancer. 2007 Jun;43(9):1452-9. doi: 10.1016/j.ejca.2007.03.004. Epub 2007 Apr 17. Eur J Cancer. 2007. PMID: 17442564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,175 results

Search Page

Filters